The Oncomine BCR IGHV Leader-J Assay is a targeted next-generation sequencing (NGS) assay for detection of somatic hypermutation (SHM) in the variable region of the immunoglobulin heavy chain of B-cell receptors. SHM increases the affinity of the B-cell receptor for antigen, post-VDJ recombination, and is used as a biomarker in chronic lymphocytic leukemia (CLL). Primers have been specifically designed to target the leader and joining regions of the immunoglobulin heavy chain, resulting in an amplicon ∼480 bp in length. When combined with Ion Reporter Software, you can easily analyze your data and create reports within a short period of time.

Key features of the Oncomine BCR IGHV Leader-J Assay:
• Sequencing of variable region of IGH; primer from Leader and Joining regions
• Assay meets current ERIC guidelines for research in CLL
• Coverage of entire IGH variable gene for accurate measurement of somatic hypermutation rate
• Optimized Oncomine informatics for easy, all-inclusive analysis and publication-ready data plots

The kit provides reagents for library construction, including dNTPs. Ion AmpliSeq libraries can be generated from DNA extracted from fresh/frozen tissue, bone marrow, whole blood, peripheral blood leukocytes, PBMCs, and sorted B cells with as little as 50 ng of nucleic acid per pool. The assay is optimized for sequencing on the Ion GeneStudio S5 System with Ion 530 chips to enable up to eight samples per run.

When the primary test isn’t enough
Often when the desired results are not achieved with a primary test, an assay designed with primers directed to different regions of the V(D)J region can be used as a secondary or follow-up test to improve sensitivity of detection. Where needed, alternate priming can be achieved through secondary testing of the samples using the Oncomine IGH FR1-J Assay (Cat. No. A52564).